StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Vaxart gross margin

Gross margin is gross profit as a percentage of revenue.

Vaxart's gross margin for the twelve months ending Jun 30, 2016 was -271.0%. For fiscal 2015 it was 85.4%, against 25.6% the year before. The highest annual figure on record is 85.4% in fiscal 2015.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2015Jun 30, 201585.4%+59.7
FY2014Jun 30, 201425.6%−15.8
FY2013Jun 30, 201341.4%−10.1
FY2012Jun 30, 201251.5%−29.6
FY2009Dec 26, 200981.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2016CQ2 2016Jun 30, 2016-1133.3%−645.5
Q3 FY2016CQ1 2016Mar 31, 2016-98.1%–
Q2 FY2016CQ4 2015Dec 31, 2015-382.4%–
Q1 FY2016CQ3 2015Sep 30, 2015-394.1%–
Q4 FY2015CQ2 2015Jun 30, 2015-487.8%–

More Vaxart figures

See a number that looks wrong?